Vision and Mission

To be the most valuable  radiopharmaceutical company in China, and  one of the world's leaders.

Bring  new hope to patients by developing  the most innovative radioactive diagnostic and therapeutic products.

Suzhou Smart Nuclide Pharmaceutical Technology Company was founded in 2015, providing innovative diagnostic and therapeutic radiopharmaceuticals for patients around the world. Our products focus on thyroid cancer, precision radioactive imaging and targeted radioligand therapy. Since its foundation, Smart Nuclide has raised over 200 million yuan with four rounds of venture capital investment.
In Smart Nuclide, we build several technology platforms focusing on the discovery, R&D, and production of radiopharmaceuticals based on single-domain antibody, with independent intellectual property rights...